Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
China reports positive Phase 3 results for ruxolitinib cream in treating atopic dermatitis, showing strong efficacy and safety.
China Medical System reported positive Phase 3 trial results for ruxolitinib cream in treating mild to moderate atopic dermatitis in China, meeting primary and secondary endpoints with significantly higher improvement rates compared to placebo.
The treatment showed strong efficacy and was well-tolerated, with no serious side effects leading to discontinuation.
The drug, already approved in the U.S. and Europe, is being advanced for approval in China, with existing access in Hong Kong, Macau, and Guangdong under a regional healthcare initiative.
It targets a significant unmet need for millions affected by the chronic skin condition.
China informa resultados positivos de la fase 3 para la crema de ruxolitinib en el tratamiento de la dermatitis atópica, que muestran una fuerte eficacia y seguridad.